XON - Intrexon Corporation

NYSE - NYSE Delayed Price. Currency in USD
14.75
+0.08 (+0.55%)
At close: 4:03PM EDT
Stock chart is not supported by your current browser
Previous Close14.67
Open14.69
Bid0.00 x 0
Ask0.00 x 0
Day's Range14.60 - 15.00
52 Week Range10.26 - 23.80
Volume2,420,881
Avg. Volume1,364,469
Market Cap1.929B
Beta1.69
PE Ratio (TTM)N/A
EPS (TTM)-1.04
Earnings DateAug 7, 2018 - Aug 13, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est23.00
Trade prices are not sourced from all markets
  • Cramer's lightning round: Medical device stocks tend to w...
    CNBC Videoslast month

    Cramer's lightning round: Medical device stocks tend to w...

    Jim Cramer rattles off his take on callers' favorite stocks, including a group of securities he tends to recommend.

  • ACCESSWIRE11 days ago

    Free Technical Research on Intrexon and Three More Biotech Equities

    LONDON, UK / ACCESSWIRE / July 11, 2018 / If you want a free Stock Review on XON sign up now at www.wallstequities.com/registration. On Tuesday, July 10, 2018, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged higher at the closing bell. Seven out of nine sectors ended Tuesday's trading session in bullish territories.

  • Company Lends Stock to Bank. Bank Shorts Stock to Company's CEO. Any Questions?
    Bloomberg12 days ago

    Company Lends Stock to Bank. Bank Shorts Stock to Company's CEO. Any Questions?

    Intrexon Corp. is a $1.9 billion market-cap biotech company that issued $200 million of convertible bonds last week. The way convertible bonds work is that they are bonds that can be converted into stock: You sell them for $1,000, and at the end of (in this case) five years investors either get a fixed number of shares of stock (if the stock is up more than a certain amount over those five years) or just get their $1,000 back. If short sellers are already selling a lot of a company’s stock short, then there may not be much stock left to borrow.

  • Deutsche Bank Brought in Some Help
    Bloomberg12 days ago

    Deutsche Bank Brought in Some Help

    Hedge fund managers will decide that they’re better at operating businesses than business operators are, and become activists, and get companies to adopt their operational suggestions. As a private-equity investor, Cerberus often provides advice for a fee to its portfolio companies.

  • PR Newswire23 days ago

    Intrexon Announces Pricing of Offerings of Convertible Senior Notes and Common Stock

    GERMANTOWN, Md., June 29, 2018 /PRNewswire/ -- Intrexon Corporation (XON) (the "Company") today announced that it has priced its offering of $200.0 million aggregate principal amount of its 3.50% Convertible Senior Notes due 2023 (the "Notes") in an underwritten offering registered with the Securities and Exchange Commission (the "SEC"). The Notes will be senior unsecured obligations of the Company and will bear interest at a rate of 3.50% per year, payable semiannually in arrears on January 1 and July 1 of each year, beginning on January 1, 2019.  The Notes will mature on July 1, 2023, unless earlier repurchased or converted in accordance with their terms.  Prior to April 1, 2023, the Notes will be convertible at the option of the holder only upon the occurrence of certain events and during certain periods.  On or after April 1, 2023, the Notes will be convertible at the option of the holder at any time until the business day immediately preceding the maturity date.

  • GlobeNewswire24 days ago

    Ziopharm Oncology Enrolls First Patient in Phase 1 Trial Evaluating Combination Therapy of Controlled IL-12 and OPDIVO®

    Ziopharm Oncology, Inc. (ZIOP), a biotechnology company focused on development of next generation immunotherapies utilizing gene- and cell-based therapies to treat patients with cancer, today announced that it has enrolled the first patient in its Phase 1 clinical trial to evaluate Ad-RTS-hIL-12 plus veledimex in combination with OPDIVO® (nivolumab), an immune checkpoint, or PD-1, inhibitor, in adult patients with recurrent glioblastoma (rGBM). “We are excited about the first-ever dosing of this combination and its potential to bring a potent and controlled anti-tumor immune response to glioblastoma,” said Francois Lebel, M.D., Executive Vice President, Research and Development, Chief Medical Officer at Ziopharm. “By controlling interleukin 12, Ad-RTS-hIL-12 plus veledimex already has shown it can recruit killer T cells into the tumor and increase expression of checkpoints in this microenvironment.

  • PR Newswire25 days ago

    Intrexon Announces Proposed Offerings of Convertible Senior Notes and Common Stock

    GERMANTOWN, Md., June 27, 2018 /PRNewswire/ -- Intrexon Corporation (XON) (the "Company") today announced that it intends to offer and sell, subject to market and other conditions, $200.0 million aggregate principal amount of its Convertible Senior Notes due 2023 (the "Notes") in an underwritten offering registered with the Securities and Exchange Commission (the "SEC").  The Company expects to grant the underwriters of the Notes a 30-day option to purchase up to an additional $30.0 million aggregate principal amount of Notes, solely to cover over-allotments, if any. The Notes will be senior unsecured obligations of the Company, and interest will be payable semi-annually in arrears.  The Notes will be convertible into cash, shares of the Company's common stock ("Common Stock") or a combination thereof, at the Company's election.  The interest rate, conversion rate and other terms of the Notes will be determined upon pricing of the offering of the Notes.

  • ACCESSWIRElast month

    Today's Research Reports on Trending Tickers: Regeneron Pharmaceuticals and Intrexon

    NEW YORK, NY / ACCESSWIRE / June 20, 2018 / U.S. equities slumped on Tuesday as global trade concerns grew after President Trump threatened to impose an additional $400 billion in tariffs on goods from ...

  • PR Newswirelast month

    Oxitec to Apply New Generation of Self-limiting Mosquito Technology to Malaria-spreading Mosquitoes

    Oxitec, Ltd. ("Oxitec"), a wholly owned subsidiary of Intrexon Corporation (XON), today announced it is entering into a cooperative agreement with the Bill & Melinda Gates Foundation ("BMGF") to develop a new strain of Oxitec's self-limiting Friendly™ Mosquitoes to combat a mosquito species that spreads malaria in the Western Hemisphere. The parties will build on Oxitec's successful deployment of Friendly™ Aedes mosquitoes to reduce the vector that spreads dengue, Zika and other diseases and apply the self-limiting and male-selecting technology to anopheline vectors that can spread malaria in endemic regions in the Americas, eastern Africa and South Asia.

  • PR Newswirelast month

    Oxitec to Apply New Generation of Self-limiting Mosquito Technology to Malaria-spreading Mosquitoes

    Oxitec, Ltd. ("Oxitec"), a wholly owned subsidiary of Intrexon Corporation (XON) (XON), today announced it is entering into a cooperative agreement with the Bill & Melinda Gates Foundation ("BMGF") to develop a new strain of Oxitec's self-limiting Friendly™ Mosquitoes to combat a mosquito species that spreads malaria in the Western Hemisphere. The parties will build on Oxitec's successful deployment of Friendly™ Aedes mosquitoes to reduce the vector that spreads dengue, Zika and other diseases and apply the self-limiting and male-selecting technology to anopheline vectors that can spread malaria in endemic regions in the Americas, eastern Africa and South Asia.

  • CNBClast month

    Cramer's lightning round: Medical device stocks tend to win big

    Jim Cramer rattles off his take on callers' favorite stocks, including a group of securities he tends to recommend.

  • GlobeNewswirelast month

    Ziopharm Oncology Reports on Status of Investigational New Drug Application for Phase 1 Trial to Evaluate CD19-targeted CAR T Therapy

    Ziopharm, Precigen, Inc., a wholly-owned subsidiary of Intrexon Corporation (XON) and The University of Texas MD Anderson Cancer Center, the IND sponsor, are seeking to conduct a clinical trial to evaluate CAR+ T cells manufactured with Sleeping Beauty technology as an investigational treatment for patients with relapsed or refractory, CD19+ leukemias and lymphomas. CAR+ T cells very-rapidly manufactured with the Sleeping Beauty platform for this third-generation trial are designed to co-express CD19-specific chimeric antigen receptor, or CAR, membrane-bound interleukin 15 and a safety switch.

  • Intrexon (XON) Down 9.2% Since Earnings Report: Can It Rebound?
    Zackslast month

    Intrexon (XON) Down 9.2% Since Earnings Report: Can It Rebound?

    Intrexon (XON) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • GlobeNewswire2 months ago

    Ziopharm Oncology Presents Clinical Data Demonstrating Anti-tumor Immune Response of Controlled IL-12 Platform in Breast Cancer and Glioblastoma at American Society of Clinical Oncology (ASCO) Annual Meeting

    -Ad-RTS-hIL-12 plus veledimex recruits T cells into breast and brain cancers- Median overall survival reaches 12.7 months in patients with recurrent glioblastoma in 20 mg veledimex cohort who received ...

  • Does Intrexon Corporation’s (NYSE:XON) Latest Financial Perfomance Look Strong?
    Simply Wall St.2 months ago

    Does Intrexon Corporation’s (NYSE:XON) Latest Financial Perfomance Look Strong?

    When Intrexon Corporation (NYSE:XON) released its most recent earnings update (31 March 2018), I compared it against two factor: its historical earnings track record, and the performance of its industryRead More...

  • PR Newswire2 months ago

    Isolation and Recombinant Expression of Key Enzyme for Opioid Production

    Long Postulated Enzyme Thebaine Synthase Potentiates Efficient Biosynthesis of Opioids by Increasing Thebaine Titers 20-fold in Engineered Yeast Strains BUDAPEST, Hungary , May 29, 2018 /PRNewswire/ ...

  • PR Newswire2 months ago

    Oxitec Launches Field Trial in Brazil for Next Generation Addition to Friendly™ Mosquitoes Platform

    Oxitec Ltd, a wholly owned subsidiary of Intrexon Corporation (XON), announced that the newest addition to its Friendly™ Aedes aegypti mosquito line, "OX5034", will initiate open field trials on May 23, 2018. OX5034 is the next generation of Oxitec's non-biting Friendly™ Aedes mosquitoes, designed to reduce populations of the disease-spreading Aedes aegypti mosquito. This first field trial of this second generation Friendly™ Aedes mosquito will take place in Indaiatuba, a municipality in the state of São Paulo and part of the metropolitan region of Campinas, Brazil.

  • PR Newswire2 months ago

    The Cayman Government and Oxitec Launch Innovative Pilot to Suppress Aedes aegypti

    The Cayman Islands' Mosquito Research and Control Unit (MRCU) and Oxitec Ltd. (XON) announced today the launch of a new partnership this year as part of the MRCU's efforts to combat Aedes aegypti mosquitoes in the Cayman Islands. The partnership will focus on implementing a new pilot project that will integrate Oxitec's Friendly™ Aedes aegypti mosquitoes with more traditional methods used in integrated vector management ("IVM") efforts, allowing for the evaluation of a combined approach designed to dramatically suppress this vector of Zika, dengue, yellow fever, and chikungunya.

  • PR Newswire2 months ago

    The Cayman Government and Oxitec Launch Innovative Pilot to Suppress Aedes aegypti

    The Cayman Islands' Mosquito Research and Control Unit (MRCU) and Oxitec Ltd. announced today the launch of a new partnership this year as part of the MRCU's efforts to combat Aedes aegypti mosquitoes in the Cayman Islands. The partnership will focus on implementing a new pilot project that will integrate Oxitec's Friendly™ Aedes aegypti mosquitoes with more traditional methods used in integrated vector management ("IVM") efforts, allowing for the evaluation of a combined approach designed to dramatically suppress this vector of Zika, dengue, yellow fever, and chikungunya.

  • Precigen Announces First Patient Dosed in Phase 1 Clinical Study of INXN-4001
    PR Newswire2 months ago

    Precigen Announces First Patient Dosed in Phase 1 Clinical Study of INXN-4001

    GERMANTOWN, Md., May 21, 2018 /PRNewswire/ -- Precigen, Inc., a wholly-owned subsidiary of Intrexon Corporation and a biopharmaceutical company specializing in the development of innovative gene and cellular therapies to improve the lives of patients, today announced the treatment of the first patient in a Phase 1 first-in-human clinical trial of its investigational therapy, INXN-4001. "This start of dosing is an exciting and important milestone for Precigen as INXN-4001 is the first investigational new drug (IND) application filed and the first patient dosed for Precigen as a newly formed wholly-owned subsidiary of Intrexon," said Helen Sabzevari, PhD, president of Precigen.

  • GlobeNewswire2 months ago

    Ziopharm Oncology to Present Data from Clinical Studies of Controlled IL-12 in Breast Cancer and Glioblastoma at American Society of Clinical Oncology (ASCO) Annual Meeting

    -Data from biopsies shows Ad-RTS-hIL-12 plus veledimex recruits killer T cells into breast and brain cancers. -IL-12 continues to demonstrate activity as a single-agent therapy, prolongs survival in patients ...

  • GlobeNewswire2 months ago

    Recent Analysis Shows H&R Block, Opko Health, Geron, Cardinal Health, Corning, and Intrexon Market Influences — Renewed Outlook, Key Drivers of Growth

    NEW YORK, May 16, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of H&R ...

  • ACCESSWIRE2 months ago

    Today’s Research Reports on Stocks to Watch: Intrexon and Supernus Pharmaceuticals

    NEW YORK, NY / ACCESSWIRE / May 14, 2018 / While one biotech company went up, the other went down on Friday. Intrexon shares tanked on Friday over first quarter results that didn’t impress traders, as shares of Supernus Pharmaceuticals were galloping ahead on a strong first quarter report. Intrexon Corporation shares closed down almost 20% on Friday with a little over 5 million shares traded.

  • PR Newswire2 months ago

    Intrexon to Participate in the Bank of America Merrill Lynch 2018 Healthcare Conference

    GERMANTOWN, Md. , May 14, 2018 /PRNewswire/ --  Intrexon Corporation (NYSE: XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, today ...

  • ACCESSWIRE2 months ago

    Free Breakfast Technical Briefing on Intrexon and Three Other Biotech Stocks

    Under assessment are the following four stocks: Intrexon Corp. (NYSE: XON), Iovance Biotherapeutics Inc. (NASDAQ: IOVA), Jaguar Health Inc. (NASDAQ: JAGX), and Jazz Pharmaceuticals PLC (NASDAQ: JAZZ). Germantown, Maryland-based Intrexon Corp.'s stock plummeted 19.64%, finishing last Friday's trading session at $14.98.